208 related articles for article (PubMed ID: 25548652)
1. A panel of DNA methylation markers reveals extensive methylation in histologically benign prostate biopsy cores from cancer patients.
Brikun I; Nusskern D; Gillen D; Lynn A; Murtagh D; Feczko J; Nelson WG; Freije D
Biomark Res; 2014; 2(1):25. PubMed ID: 25548652
[TBL] [Abstract][Full Text] [Related]
2. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W
Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847
[TBL] [Abstract][Full Text] [Related]
3. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
4. A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA.
Brikun I; Nusskern D; Decatus A; Harvey E; Li L; Freije D
Clin Epigenetics; 2018; 10():91. PubMed ID: 29988684
[TBL] [Abstract][Full Text] [Related]
5. Is race a positive predictor of cancer on repeat prostate biopsy?
Yanke BV; Salzhauer EW; Colon I
J Urol; 2006 Sep; 176(3):1114-7. PubMed ID: 16890704
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study.
Stewart GD; Van Neste L; Delvenne P; Delrée P; Delga A; McNeill SA; O'Donnell M; Clark J; Van Criekinge W; Bigley J; Harrison DJ
J Urol; 2013 Mar; 189(3):1110-6. PubMed ID: 22999998
[TBL] [Abstract][Full Text] [Related]
7. Atypical small acinar proliferation and two or more cores of high-grade intraepithelial neoplasia on a previous prostate biopsy are significant predictors of cancer during a transperineal template-guided saturation biopsy aimed at sampling one core for each 1 mL of prostate volume.
Nakai Y; Tanaka N; Miyake M; Hori S; Tatsumi Y; Morizawa Y; Fujii T; Konishi N; Fujimoto K
Res Rep Urol; 2017; 9():187-193. PubMed ID: 29034221
[TBL] [Abstract][Full Text] [Related]
8. Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion.
Bhindi B; Jiang H; Poyet C; Hermanns T; Hamilton RJ; Li K; Toi A; Finelli A; Zlotta AR; van der Kwast TH; Evans A; Fleshner NE; Kulkarni GS
Urol Oncol; 2017 Oct; 35(10):604.e17-604.e24. PubMed ID: 28781111
[TBL] [Abstract][Full Text] [Related]
9. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer.
Schoenfield L; Jones JS; Zippe CD; Reuther AM; Klein E; Zhou M; Magi-Galluzzi C
BJU Int; 2007 Apr; 99(4):770-4. PubMed ID: 17233800
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic risk score improves prostate cancer risk assessment.
Van Neste L; Groskopf J; Grizzle WE; Adams GW; DeGuenther MS; Kolettis PN; Bryant JE; Kearney GP; Kearney MC; Van Criekinge W; Gaston SM
Prostate; 2017 Sep; 77(12):1259-1264. PubMed ID: 28762545
[TBL] [Abstract][Full Text] [Related]
11. Parasagittal biopsies add minimal information in repeat saturation prostate biopsy.
Patel AR; Jones JS; Rabets J; DeOreo G; Zippe CD
Urology; 2004 Jan; 63(1):87-9. PubMed ID: 14751355
[TBL] [Abstract][Full Text] [Related]
12. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
[TBL] [Abstract][Full Text] [Related]
13. Quantitative GSTP1 methylation levels correlate with Gleason grade and tumor volume in prostate needle biopsies.
Zhou M; Tokumaru Y; Sidransky D; Epstein JI
J Urol; 2004 Jun; 171(6 Pt 1):2195-8. PubMed ID: 15126784
[TBL] [Abstract][Full Text] [Related]
14. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
15. Initial diagnosis of insignificant cancer, high-grade prostatic intraepithelial neoplasia, atypical small acinar proliferation, and negative have the same rate of upgrade to a Gleason score of 7 or higher on repeat prostate biopsy.
Prathibha S; Goyal KG; Zynger DL
Hum Pathol; 2018 Sep; 79():116-121. PubMed ID: 29803813
[TBL] [Abstract][Full Text] [Related]
16. Incidence of Clinically Significant Prostate Cancer After a Diagnosis of Atypical Small Acinar Proliferation, High-grade Prostatic Intraepithelial Neoplasia, or Benign Tissue.
Wiener S; Haddock P; Cusano J; Staff I; McLaughlin T; Wagner J
Urology; 2017 Dec; 110():161-165. PubMed ID: 28888752
[TBL] [Abstract][Full Text] [Related]
17. Can the number of cores with high-grade prostate intraepithelial neoplasia predict cancer in men who undergo repeat biopsy?
Naya Y; Ayala AG; Tamboli P; Babaian RJ
Urology; 2004 Mar; 63(3):503-8. PubMed ID: 15028446
[TBL] [Abstract][Full Text] [Related]
18. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR.
Rosenkrantz AB; Verma S; Choyke P; Eberhardt SC; Eggener SE; Gaitonde K; Haider MA; Margolis DJ; Marks LS; Pinto P; Sonn GA; Taneja SS
J Urol; 2016 Dec; 196(6):1613-1618. PubMed ID: 27320841
[TBL] [Abstract][Full Text] [Related]
19. Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study.
Wojno KJ; Costa FJ; Cornell RJ; Small JD; Pasin E; Van Criekinge W; Bigley JW; Van Neste L
Am Health Drug Benefits; 2014 May; 7(3):129-34. PubMed ID: 24991397
[TBL] [Abstract][Full Text] [Related]
20. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
